4.7 Article

Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 559, Issue -, Pages 220-227

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2019.01.042

Keywords

Gemcitabine; Paclitaxel; Hydrogel; Nanomedicine; Glioblastoma; Local delivery

Funding

  1. Education, Audiovisual and Culture Executive Agency (EACEA) of the European Commission
  2. EuroNanoMed 3 fund Gliogel
  3. La fondation contre le cancer (Belgium) [FAF-C/2016/830]

Ask authors/readers for more resources

Lauroyl-gemcitabine lipid nanocapsules (GemC(12)-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC(12)-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC(12)-LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC(12)-LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC(12)-LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC(12). Our results suggest that GemC(12)-LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available